NEW YORK (GenomeWeb) – New research by a University of Texas MD Anderson Cancer Center-led team has untangled some of the factors that influence checkpoint inhibitor treatment response in metastatic melanoma.
Get the full story This story is free
for registered users
Registering provides access to this and other free content.
Already have an account?